Glax­o­SmithK­line’s head of vac­cine R&D is jump­ing to a well­ness com­pa­ny con­cen­trat­ing on the mi­cro­bio­me as re­ports of an ex­o­dus start to spread

Back in the fall of 2019, Glax­o­SmithK­line vac­cine R&D chief Em­manuel Hanon had plen­ty of good things to say about a well­ness com­pa­ny called Viome and CEO Naveen Jain. He was par­tic­u­lar­ly in­ter­est­ed in Viome’s tech­nol­o­gy for an­a­lyz­ing the gut mi­cro­bio­me and how that could in­ter­sect with new vac­cine re­search.

To­day, Hanon is jump­ing ship to join his col­lab­o­ra­tor as R&D chief as re­ports cir­cu­late of an ex­o­dus at GSK’s big vac­cine group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER